![Austin Hill](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Blair R. Leavitt | M | - |
Incisive Genetics, Inc.
![]() Incisive Genetics, Inc. BiotechnologyHealth Technology Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018. | 6 anni |
Karen Boodram | F | - |
Incisive Genetics, Inc.
![]() Incisive Genetics, Inc. BiotechnologyHealth Technology Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018. | - |
Pamela Wagner | F | - |
Incisive Genetics, Inc.
![]() Incisive Genetics, Inc. BiotechnologyHealth Technology Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018. | 6 anni |
Noel F. Hall | M | - |
Incisive Genetics, Inc.
![]() Incisive Genetics, Inc. BiotechnologyHealth Technology Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018. | - |
Brian Curin | M | - |
Incisive Genetics, Inc.
![]() Incisive Genetics, Inc. BiotechnologyHealth Technology Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018. | - |
Kevin Chow | M | 54 |
Incisive Genetics, Inc.
![]() Incisive Genetics, Inc. BiotechnologyHealth Technology Incisive Genetics, Inc. is a privately held biotechnology company based in an undisclosed location, established in 2018. The Canadian company has developed a cutting-edge non-viral delivery platform for genetic therapies called Omnia™. This platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The company's pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. The company was founded in 2018 by Blair R. Leavitt, Austin Hill, and Pamela Wagner. Blair R. Leavitt has been the CEO since 2018. | 3 anni |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Canada | 6 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Austin Hill
- Contatti personali